Another is to surgically implant them onto the retina using a piece of synthetic or natural material, known as scaffolding ... gene therapy may displace anti-VEGF injection as the preferred form of ...

Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...

Macular degeneration is very common and affects an estimated 19.8 million people in the ... Laser surgery: Shining a laser light beam on abnormal blood vessels may reduce their quantity and slow their ...

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Age-related macular ... degeneration. But just because a technology doesn’t exist right now doesn’t mean it won’t in the future. There’s always the possibility that a new treatment ...

In the last 20 years, there have been rapid advances in the treatment options for myopic ... it is possible that patients with myopic macular degeneration complicated by CNV may benefit from ...

Retinitis pigmentosa is a relatively rare genetic disorder (affecting 1 in 3,500 people), while age-related macular degeneration ... which allows for more natural vision." "In pre-clinical models ...